Previous research has demonstrated the role of IFN pathways in COVID-19 protection, with nasal IFN-α being useful in preventing influenza and rhinovirus, 2 respiratory viruses that are acquired in the community. This trial assessed whether giving adult cancer patients a daily nasal spray of IFN-α would lower their risk of contracting COVID-19 or other community-acquired respiratory viral infections.
The participants in this study were randomized 1:1 to receive either a normal saline placebo or a daily 40 000 IU IFN-α nasal spray. To test for SARS-CoV-2, influenza A/B, parainfluenza, adenovirus, respiratory syncytial virus, picornavirus, human metapneumovirus, seasonal coronavirus, and/or SARS-CoV-2 rapid antigen, participants who experienced influenza-like symptoms self-collected nose swabs. Incidence of COVID-19 and/or other respiratory viruses within 90 days of randomization were co-primary outcomes.
A total of 433 individuals were randomly assigned to either IFN-α (n = 217) or a placebo (n = 216). When compared to the placebo group, the IFN-α group had a lower incidence of COVID-19 (8.3% vs. 14.4%), suggesting a 40% lower chance of infection (relative risk [RR]:.60; 95% credible interval [CrI]:.33–.97).
In both groups, the incidence of other respiratory viral infections was 5.1% (RR: 1.12;.43–2.34). The incidence of COVID-19 was 7.7% in the IFN-α group and 16.0% in the placebo group (RR:.50;.26–.84) in the per-protocol cohort (n = 389), whereas the incidence of other respiratory viruses was 4.6% and 5.7%, respectively.
There was no difference by underlying malignancy, but subgroup analysis showed decreased COVID-19 in the IFN-α group for ages <65 years (RR:.48;.20–.92), female sex (RR:.44;.19–.85), and COVID-19 vaccinated (RR:.50;.26–.82). Hospitalization, death, and secondary endpoints of severity did not vary. IFN-α was safe and well tolerated.
Overall, prophylactic use of intranasal IFN-α nasal spray was safe and beneficial in lowering the incidence of COVID-19 in adult cancer patients. In addition to immunization and monoclonal antibodies, IFN-α may be a preventative approach against COVID-19.
Source:
Yong, M. K., Thursky, K., Crane, M., Spelman, T., Mahar, R. K., Simpson, J. A., Scott, A. M., Harrison, S. J., Szer, J., Pellegrini, M., Lingaratnam, S., Pang, K. C., Tennakoon, S., Sim, B. Z., Blyth, E., Gan, H. K., Quach, H., McIntosh, M. P., Page, H., … Slavin, M. (2025). Interferon-α nasal spray prophylaxis reduces COVID-19 in cancer patients: A randomized, double-blinded, placebo-controlled trial. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America,. https://doi.org/10.1093/cid/ciaf409
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.